2020 Q2 Form 10-Q Financial Statement
#000156459020034763 Filed on July 30, 2020
Income Statement
| Concept | 2020 Q2 | 2019 Q2 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $46.70M | $12.80M |
| YoY Change | 264.84% | 116.95% |
| % of Gross Profit | ||
| Research & Development | $87.09M | $50.70M |
| YoY Change | 71.79% | 84.11% |
| % of Gross Profit | ||
| Depreciation & Amortization | $90.00K | $50.00K |
| YoY Change | 80.0% | |
| % of Gross Profit | ||
| Operating Expenses | $115.5M | $50.70M |
| YoY Change | 127.83% | 84.11% |
| Operating Profit | -$115.5M | -$63.48M |
| YoY Change | 81.97% | 89.56% |
| Interest Expense | -$3.100M | -$7.800M |
| YoY Change | -60.26% | -4338.92% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $5.000K | $200.0K |
| YoY Change | -97.5% | -708.51% |
| Pretax Income | -$118.6M | -$71.10M |
| YoY Change | 66.81% | 113.51% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$118.6M | -$71.09M |
| YoY Change | 66.85% | 113.26% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | -$1.57 | |
| Diluted Earnings Per Share | -$1.57 | -$1.123M |
| COMMON SHARES | ||
| Basic Shares Outstanding | 75.51M | 63.23M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q2 | 2019 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $832.8M | $289.1M |
| YoY Change | 188.07% | 13.91% |
| Cash & Equivalents | $317.3M | $289.1M |
| Short-Term Investments | $515.5M | |
| Other Short-Term Assets | $21.00M | $3.356M |
| YoY Change | 525.75% | 43512.67% |
| Inventory | ||
| Prepaid Expenses | $13.98M | |
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $853.8M | $308.4M |
| YoY Change | 176.84% | 15.64% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $15.40M | $1.439M |
| YoY Change | 970.11% | |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $900.0K | $207.9K |
| YoY Change | 332.96% | 78.97% |
| Total Long-Term Assets | $16.30M | $8.291M |
| YoY Change | 96.59% | 7038.44% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $853.8M | $308.4M |
| Total Long-Term Assets | $16.30M | $8.291M |
| Total Assets | $870.1M | $316.7M |
| YoY Change | 174.74% | 18.7% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $9.900M | $13.81M |
| YoY Change | -28.32% | 169.08% |
| Accrued Expenses | $45.40M | $20.23M |
| YoY Change | 124.42% | 295.02% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $0.00 | |
| YoY Change | ||
| Total Short-Term Liabilities | $58.00M | $35.59M |
| YoY Change | 62.96% | 247.09% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $348.8M | $6.700M |
| YoY Change | 5105.97% | -75.0% |
| Other Long-Term Liabilities | $231.2M | $250.0K |
| YoY Change | 92380.0% | -16.67% |
| Total Long-Term Liabilities | $580.0M | $250.0K |
| YoY Change | 231900.0% | -99.08% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $58.00M | $35.59M |
| Total Long-Term Liabilities | $580.0M | $250.0K |
| Total Liabilities | $638.0M | $157.6M |
| YoY Change | 304.78% | 322.57% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$398.4M | |
| YoY Change | 94.99% | |
| Common Stock | $6.367K | |
| YoY Change | 13.39% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $232.1M | $159.1M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $870.1M | $316.7M |
| YoY Change | 174.74% | 18.7% |
Cashflow Statement
| Concept | 2020 Q2 | 2019 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$118.6M | -$71.09M |
| YoY Change | 66.85% | 113.26% |
| Depreciation, Depletion And Amortization | $90.00K | $50.00K |
| YoY Change | 80.0% | |
| Cash From Operating Activities | -$94.29M | -$39.91M |
| YoY Change | 136.26% | 30.04% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$530.0K | -$190.0K |
| YoY Change | 178.95% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$287.3M | |
| YoY Change | ||
| Cash From Investing Activities | -$287.8M | -$190.0K |
| YoY Change | 151378.95% | |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 281.7M | 40.96M |
| YoY Change | 587.67% | -68.88% |
| NET CHANGE | ||
| Cash From Operating Activities | -94.29M | -39.91M |
| Cash From Investing Activities | -287.8M | -190.0K |
| Cash From Financing Activities | 281.7M | 40.96M |
| Net Change In Cash | -100.4M | 860.0K |
| YoY Change | -11777.91% | -99.15% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$94.29M | -$39.91M |
| Capital Expenditures | -$530.0K | -$190.0K |
| Free Cash Flow | -$93.76M | -$39.72M |
| YoY Change | 136.05% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P5Y3D | |
| CY2020Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y6M25D | |
| us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
91178000 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
20949000 | ||
| us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-65636000 | ||
| us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-9840000 | ||
| us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
3300000 | ||
| us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
2288000 | ||
| apls |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
10828000 | ||
| apls |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
753000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
20000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-25000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-287439000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-121665000 | ||
| CY2020Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-842000 | |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
552000 | ||
| CY2020Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
161000 | |
| CY2019Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-1000 | |
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-69000 | ||
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
1000 | ||
| CY2020Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-681000 | |
| CY2019Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-1000 | |
| us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
483000 | ||
| us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
1000 | ||
| CY2020Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-119298000 | |
| CY2019Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-71091000 | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-286956000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-121664000 | ||
| CY2020Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.57 | |
| CY2019Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.12 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-3.85 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.01 | ||
| CY2020Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
75550 | |
| CY2019Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
63264 | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
74635 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
60581 | ||
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
1394000 | |
| CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
35000 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1355000 | |
| CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
11489000 | |
| CY2020Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-842000 | |
| CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
|
122147000 | |
| CY2020Q2 | apls |
Adjustments To Additional Paid In Capital Purchase Of Capped Call Transactions And Associated Costs
AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsAndAssociatedCosts
|
-43112000 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
521000 | |
| CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-118617000 | |
| CY2020Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
161000 | |
| CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
232064000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
160972000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
109604000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
192000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4559000 | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-33389000 | ||
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-50574000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
2000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
224755000 | |
| CY2019Q2 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
23000 | |
| CY2019Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1262000 | |
| CY2019Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4183000 | |
| CY2019Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-71090000 | |
| CY2019Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-1000 | |
| CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
159086000 | |
| us-gaap |
Profit Loss
ProfitLoss
|
-287439000 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
-121665000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
20783000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
8742000 | ||
| us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-1208000 | ||
| us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-65636000 | ||
| us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-9840000 | ||
| apls |
Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
|
84000 | ||
| apls |
Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
|
149000 | ||
| us-gaap |
Depreciation
Depreciation
|
180000 | ||
| us-gaap |
Depreciation
Depreciation
|
87000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
38000 | ||
| apls |
Amortization Of Term Loan Facility Discounts
AmortizationOfTermLoanFacilityDiscounts
|
104000 | ||
| apls |
Amortization Of Discounts For Convertible Notes Net Of Financing Costs
AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts
|
5548000 | ||
| us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-1877000 | ||
| us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-10357000 | ||
| us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
824000 | ||
| us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
3527000 | ||
| us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
518000 | ||
| us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
91000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1600000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
3801000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-9570000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
15399000 | ||
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
91000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-202643000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-75467000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
973000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1067000 | ||
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
567188000 | ||
| us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
52500000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-515661000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1067000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
381423000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
109629000 | ||
| apls |
Proceeds From Development Derivative Liability
ProceedsFromDevelopmentDerivativeLiability
|
20000000 | ||
| apls |
Proceeds From Development Derivative Liability
ProceedsFromDevelopmentDerivativeLiability
|
100000000 | ||
| apls |
Payments For Capped Call Transactions And Associated Costs
PaymentsForCappedCallTransactionsAndAssociatedCosts
|
43112000 | ||
| apls |
Proceeds From Issuance Of Convertible Notes Net Of Issuance Costs
ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCosts
|
323074000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
3029000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1454000 | ||
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
521000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-20000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
112860000 | ||
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
351985000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
176268000 | |
| CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
318596000 | |
| CY2020Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
317348000 | |
| CY2019Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
289128000 | |
| CY2020Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
1248000 | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
3829000 | ||
| us-gaap |
Interest Paid Net
InterestPaidNet
|
728000 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Organization and Operations </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apellis Pharmaceuticals, Inc. (the “Company”) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was incorporated in September 2009 under the laws of the State of Delaware and has its principal office in Waltham, Massachusetts.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital and developing its product candidates. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, market acceptance of the Company’s products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration (“FDA”). Additionally, the Company is subject to risks arising from the Coronavirus Disease 2019 (COVID-19) pandemic, which could have adverse effects upon its business and operations, including on its ability to initiate, conduct and complete clinical trials.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Notes Offering </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 12, 2020, the Company completed a private offering of $300.0 million aggregate principal amount of 3.5% convertible senior notes due 2026 (the “2020 Convertible Notes”). The aggregate purchase price of the 2020 Convertible Notes was $328.9 million, which amount includes accrued interest from March 15, 2020 to, but not including, May 12, 2020. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net proceeds from the sale of the 2020 Convertible Notes were approximately $322.9 million after deducting the initial purchasers’ discounts and commissions and offering expenses payable by the Company. The Company used $43.1 million of the net proceeds from the offering to pay the cost of the capped call transactions described below. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Convertible Notes form a single series with, and have the same terms as, the Company’s $220.0 million aggregate principal amount of 3.500% convertible senior notes due 2026 issued on September 16, 2019, (the “2019 Convertible Notes”, and together with the 2020 Convertible Notes, the “Convertible Notes”), but have a different issue date, issue price, CUSIP number and different restrictions on transfer. The 2020 Convertible Notes were issued as additional notes under the indenture (the “Indenture”), dated as of September 16, 2019, by and between the Company and U.S. Bank National Association, as trustee (the “Trustee”), under which the 2019 Convertible Notes were issued. The 2020 Convertible Notes rank equal in right of payment to the 2019 Convertible Notes. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 3.5% per year payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2020. The Convertible Notes will mature on September 15, 2026, unless earlier converted, redeemed or repurchased in accordance with their terms. See Note 5 – Long-term Debt for additional information<span style="color:#202429;font-size:7pt;">.</span> </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Capped Call Transactions </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 6, 2020, concurrently with the pricing of the 2020 Convertible Notes, the Company entered into capped call transactions with two counterparties. The capped call transactions are expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of the 2020 Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted 2020 Convertible Notes, as the case may be, in the event that the market price per share of the Company’s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which is initially $39.4625 (the conversion price of the 2020 Convertible Notes) and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of such 2020 Convertible Notes. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Follow-on Public Offerings</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 13, 2020, the Company issued and sold 10,925,000 shares of its common stock at a price per share to the public of $37.00 in a follow-on public offering including an additional 1,425,000 shares of its common stock that were sold at the follow-on public offering price of $37.00 per share pursuant to the underwriters’ in full exercise of their option to purchase additional shares of common stock. The Company received net proceeds of $381.5 million after deducting underwriting discounts and commissions of $22.2 million and offering costs of $0.5 million for these transactions. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;color:#000000;">Liquidity and Financial Condition </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of July 30, 2020, the date of issuance of these unaudited condensed consolidated financial statements, the Company believes that its cash and cash equivalents of $317.3 million and marketable securities of $515.5 million as of June 30, 2020 will be sufficient to fund its operations and capital expenditure requirements for at least the next twelve months from the date of issuance of the unaudited interim consolidated financial statements. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to other life science companies in the development stage including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, and compliance with FDA and other government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability. Management’s plans in order to meet its short-term and longer-term operating cash flow requirements include obtaining additional funding. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are uncertainties associated with the Company’s ability to (1) obtain additional debt or equity financing on terms that are favorable to the Company (2) enter into collaborative agreements with strategic partners to obtain funding, and (3) succeed in its future operations. If the Company is not able to obtain the required funding for its operations on a timely basis on terms that are favorable to the Company or at all, it could be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts and its business could be materially harmed. </p> | ||
| CY2020Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
317300000 | |
| CY2020Q2 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
515500000 | |
| CY2020Q2 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1200000 | |
| CY2019Q2 | apls |
Development Derivative Liabilities Noncurrent
DevelopmentDerivativeLiabilitiesNoncurrent
|
109840000 | |
| CY2020Q2 | apls |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
23815000 | |
| CY2019Q4 | apls |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
36449000 | |
| CY2020Q2 | apls |
Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
|
11598000 | |
| CY2019Q4 | apls |
Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
|
11443000 | |
| CY2020Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
9986000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
6891000 | |
| CY2020Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
45399000 | |
| CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
54783000 | |
| CY2019Q4 | apls |
Development Derivative Liabilities Noncurrent
DevelopmentDerivativeLiabilitiesNoncurrent
|
134839000 | |
| CY2020Q1 | apls |
Minimum Payment Of Additional Funding Amount
MinimumPaymentOfAdditionalFundingAmount
|
20000000 | |
| CY2019Q1 | apls |
Minimum Payment Of Additional Funding Amount
MinimumPaymentOfAdditionalFundingAmount
|
60000000 | |
| CY2020Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-68406000 | |
| CY2019Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-736000 | |
| CY2020Q1 | apls |
Development Derivative Liabilities Noncurrent
DevelopmentDerivativeLiabilitiesNoncurrent
|
223245000 | |
| CY2019Q1 | apls |
Development Derivative Liabilities Noncurrent
DevelopmentDerivativeLiabilitiesNoncurrent
|
60736000 | |
| CY2019Q2 | apls |
Minimum Payment Of Additional Funding Amount
MinimumPaymentOfAdditionalFundingAmount
|
40000000 | |
| CY2020Q2 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
2770000 | |
| CY2019Q2 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-9104000 | |
| CY2020Q2 | apls |
Development Derivative Liabilities Noncurrent
DevelopmentDerivativeLiabilitiesNoncurrent
|
220475000 | |
| us-gaap |
Lessee Operating Lease Description
LesseeOperatingLeaseDescription
|
The Company enters into lease agreements with terms generally ranging from 2-7 years. Some of the Company’s lease agreements include Company options to extend the lease on a month to month basis or for set periods for up to five years. Many leases also include options to terminate the leases within one year or per other contractual terms. Renewal and termination options were generally not included in the lease term for the Company’s existing operating leases. | ||
| apls |
Lessee Operating Lease Maximum Term Of Options To Terminate Lease
LesseeOperatingLeaseMaximumTermOfOptionsToTerminateLease
|
P1Y | ||
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
7287000 | ||
| CY2020Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
12959000 | |
| CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
14110000 | |
| CY2020Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
13399000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
14466000 | |
| CY2020Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0830 | |
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0819 | |
| CY2020Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1000000.0 | |
| CY2019Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
500000 | |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
2000000.0 | ||
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
900000 | ||
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
2056000 | ||
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
713000 | ||
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
334000 | ||
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
1872000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
3519000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
3283000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
3288000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
4107000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
16069000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
2670000 | |
| CY2020Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
13399000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
1164000 | |
| CY2020Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-681000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
2000 | |
| CY2019Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-1000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
0 | |
| CY2020Q2 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | |
| us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | ||
| CY2019Q2 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | |
| CY2019Q2 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | |
| us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | ||
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | ||
| CY2020Q2 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | |
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | ||
| CY2020Q2 | apls |
Estimated Termination Costs And Other Fees
EstimatedTerminationCostsAndOtherFees
|
1800000 | |
| us-gaap |
Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
|
14100000 | ||
| CY2020Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
25358000 | |
| CY2019Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9109000 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
25358000 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9109000 |
